Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Arumugam, Ramalingam
NCT04779320 / 2020-004301-31: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)	Recruiting	3	120	Europe, Canada, Japan, US, RoW	Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002	Takeda, Takeda Development Center Americas, Inc.	Crohn's Disease (CD)	11/24	11/24
MLN0002-3024, NCT04779307 / 2020-004300-34: A Study of Vedolizumab in Children and Teenagers with Moderate to Severe Ulcerative Colitis (UC)	Active, not recruiting	3	121	Europe, Canada, Japan, US, RoW	Vedolizumab, MLN0002, ENTYVIO, KYNTELES	Takeda, Takeda Development Center Americas, Inc.	Colitis, Ulcerative	08/25	08/25
NCT05442567 / 2021-000630-34: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)	Recruiting	3	240	Europe, Canada, Japan, US, RoW	Vedolizumab IV, MLN0002, ENTYVIO, KYNTELES, No Intervention	Takeda, Takeda Development Center Americas, Inc.	Ulcerative Colitis, Crohn's Disease	08/31	08/31